GreatPoint Ventures

GreatPoint Ventures concentrates on early-stage companies at the intersection of frontier technology and traditional industries. The firm invests primarily in seed and early-stage rounds, backing technical founders who apply AI, automation, and advanced data science to sectors including logistics, manufacturing, and healthcare delivery. Their approach favors deep-tech solutions that create operational efficiencies in large, established markets rather than pure consumer or enterprise software plays.

The firm's investment decisions are led by its managing partner, Andrew Perlman. Perlman's background as a founder and operator in technology and industrial innovation informs the partnership's deal evaluation. The firm operates a lean decision-making structure typical of a thesis-driven early-stage venture firm, with investments approved through a partnership consensus process rather than a broad committee.

GreatPoint typically seeks to lead or co-lead initial institutional rounds, positioning itself as a primary partner rather than a passive participant in large syndicates. The firm's strategy leans toward taking substantive ownership positions early and working closely with founding teams during the product-market-fit phase. Their value proposition centers on domain expertise and operational guidance in industrial technology and digital health.

GreatPoint targets enterprise automation, robotics, digital health, logistics, and supply-chain technology—sectors where software and AI generate measurable physical-world outcomes. The firm generally avoids consumer internet, pure-play software-as-a-service without an industrial or scientific moat, and capital-light marketplaces. Their avoidance of these categories is strategic, reflecting a commitment to the long-cycle technological innovations that define their core thesis.

GreatPoint functions as a specialist firm despite the broad applicability of the AI and automation tools its portfolio companies develop. The partnership's domain fluency in industrial technology, supply chain, and life sciences creates a differentiated sourcing and underwriting capability. This specialization means the firm competes on technical insight rather than on breadth of capital or brand recognition among generalist funds.